1.Cerebral Air Embolism after Central Venous Catheter Removal in a Patient with a Patent Foramen Ovale: A Case Report and Literature Review
Hyoung Jin HAHN ; Ghi Jai LEE ; Ki Hwan KIM ; Kyoung Eun LEE ; Jae Chan SHIM ; Dae Hyun HWANG ; Ho Kyun KIM
Journal of the Korean Radiological Society 2019;80(2):345-350
Central venous catheterization is a routinely performed procedure in clinical practice. While cerebral air embolism after the removal of the central venous catheter is very rare, it is one of the most serious complications that can lead to fatal outcomes. In this report, we present a rare case of a cerebral air embolism after the removal of the central venous catheter in a patient with a patent foramen ovale.
2.MRI Findings of Accessory Popliteus Muscle: A Case Report
Hyoung Jin HAHN ; Jae Chan SHIM ; Ki Hwan KIM ; Kyoung Eun LEE ; Dae Hyun HWANG ; Ghi Jai LEE ; Ho Kyun KIM
Journal of the Korean Radiological Society 2019;80(3):574-578
Accessory muscles located in the region of the popliteal fossa are very rare. MRI scan performed in a 52-year-old man with right knee pain revealed an anomalous muscle in the region of the popliteal fossa. Considering the muscle originated from the medial side of the lateral head of the gastrocnemius muscle and attached to the posteromedial articular capsule of the knee joint, it is consistent with the accessory popliteus muscle, previously reported. To our best knowledge, MRI finding about the accessory popliteus muscle has been reported in only one case. We present a case of the accessory popliteus muscle incidentally identified on MRI.
3.Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Dong Wan KIM ; Hoon Gu KIM ; Joo Hang KIM ; Keunchil PARK ; Hoon Kyo KIM ; Joung Soon JANG ; Bong Seog KIM ; Jin Hyoung KANG ; Kyung Hee LEE ; Sang We KIM ; Hun Mo RYOO ; Jin Soo KIM ; Ki Hyeong LEE ; Jung Hye KWON ; Jin Hyuk CHOI ; Sang Won SHIN ; Seokyung HAHN ; Dae Seog HEO
Cancer Research and Treatment 2019;51(1):119-127
PURPOSE: This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). MATERIALS AND METHODS: Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m2 intravenously on days 1 and 8+cisplatin 70 mg/m2 intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m2 intravenously on days 1, 2, 3+cisplatin 70 mg/m2 intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival. RESULTS: A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), < 65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP. CONCLUSION: The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.
Anemia
;
Arm
;
Cisplatin*
;
Diarrhea
;
Disease Progression
;
Disease-Free Survival
;
Drug Therapy
;
Etoposide*
;
Humans
;
Lung Neoplasms
;
Male
;
Nausea
;
Small Cell Lung Carcinoma*
4.Three-Dimensional Fast Spin-Echo Imaging without Fat Suppression of the Knee: Diagnostic Accuracy Comparison to Fat-Suppressed Imaging on 1.5T MRI.
Hee Woo CHO ; Jin Suck SUH ; Jin Oh PARK ; Hyoung Sik KIM ; Soo Yoon CHUNG ; Young Han LEE ; Seok HAHN
Yonsei Medical Journal 2017;58(6):1186-1194
PURPOSE: To evaluate the diagnostic performance of three-dimensional fast spin-echo (3D FSE-Cube) without fat suppression (NFS) for detecting knee lesions, using comparison to 3D FSE-Cube with fat suppression (FS). MATERIALS AND METHODS: One hundred twenty-four patients who underwent 1.5T knee magnetic resonance imaging (MRI) scans and 25 subsequent arthroscopic surgeries were retrospectively reviewed. Using arthroscopic results and two-dimensional images as reference standards, diagnostic performances of 3D FSE-Cube-NFS and FS imaging about lesions of ligament, meniscus, subchondral bone marrow edema (BME), and cartilage were compared. Scan parameters of 3D FSE-Cube imaging were previously optimized by a porcine knee phantom. RESULTS: No significant differences were observed between detection rates of NFS and FS imaging for detecting lesions of meniscus and cartilage (p>0.05). However, NFS imaging had lower sensitivity for detection of medial collateral ligament (MCL) tears, and lower sensitivity and specificity for detection of BME lesions, compared to FS imaging (p<0.05). CONCLUSION: 3D FSE-Cube-NFS imaging showed similar diagnostic performance for detecting lesions of meniscus or cartilage compared to FS imaging, unlike MCL or BME lesions.
Arthroscopy
;
Bone Marrow
;
Cartilage
;
Collateral Ligaments
;
Edema
;
Humans
;
Imaging, Three-Dimensional
;
Knee*
;
Ligaments
;
Magnetic Resonance Imaging*
;
Retrospective Studies
;
Sensitivity and Specificity
;
Tears
5.A Case of Bronchiolitis Obliterans Organizing Pneumonia Following CHOP Chemotherapy and Filgrastim Use in a Patient with Diffuse Large B-cell Lymphoma.
Wou Young CHUNG ; Min Kwang BYUN ; Jin Hyoung LEE ; Chang Hoon HAHN ; Shin Myung KANG ; Jin Seok KIM ; San Ho CHO ; Young Sam KIM ; Se Kyu KIM ; Joon CHANG ; Sung Kyu KIM ; Moo Suk PARK
Tuberculosis and Respiratory Diseases 2005;59(5):561-565
Bronchiolitis obliterans organizing pneumonia (BOOP) is often diagnosed in patients with pneumonia who respond poorly to antibiotics. BOOP is often idiopathic, and the etiology of the remaining cases has been attributed to a wide range of agents or medical conditions. When a patient develops the clinical symptoms characteristic of BOOP, the medical team must endeavor to determine the etiology of this disease because it can be treated with glucocorticoid and avoidance of the causative agent. In particular, if BOOP is diagnosed during or after chemotherapy for a malignancy, the possible culprit agent can be the anti cancer drugs but other drugs used for supportive care must be also be considered. We report a case of BOOP that arose after CHOP chemotherapy and a filgrastim injection in a patient with a diffuse large B-cell lymphoma.
Anti-Bacterial Agents
;
B-Lymphocytes*
;
Bronchiolitis Obliterans*
;
Bronchiolitis*
;
Cryptogenic Organizing Pneumonia*
;
Drug Therapy*
;
Humans
;
Lymphoma, B-Cell*
;
Pneumonia
;
Filgrastim
6.No Association between (AAT)n Repeat Polymorphisms in the Cannabinoid Receptor 1 Gene and Smooth Pursuit Eye Movement Abnormality in Korean Patients with Schizophrenia.
Min Jae KIM ; Chae Ri KIM ; Jin Wan PARK ; Doo Hyun PAK ; Hyoung Doo SHIN ; Ihn Geun CHOI ; Sang Woo HAHN ; Jaeuk HWANG ; Yeon Jung LEE ; Sung Il WOO
Journal of the Korean Society of Biological Psychiatry 2016;23(4):148-156
OBJECTIVES: According to previous studies, the cannabinoid receptor 1 (CNR1) gene could be an important candidate gene for schizophrenia. Some studies have linked the (AAT)n trinucleotide repeat polymorphism in CNR1 gene with the risk of schizophrenia. Meanwhile, smooth pursuit eye movement (SPEM) has been regarded as one of the most consistent endophenotypes of schizophrenia. In this study, we investigated the association between the (AAT)n trinucleotide repeats in CNR1 gene and SPEM abnormality in Korean patients with schizophrenia. METHODS: We measured SPEM function in 167 Korean patients with schizophrenia (84 male, 83 female) and they were divided according to SPEM function into two groups, good and poor SPEM function groups. We also investigated allele frequencies of (AAT)n repeat polymorphisms on CNR1 gene in each group. A logistic regression analysis was performed to find the association between SPEM abnormality and the number of (AAT)n trinucleotide repeats. RESULTS: The natural logarithm value of signal/noise ratio (Ln S/N ratio) of the good SPEM function group was 4.34 ± 0.29 and that of the poor SPEM function group was 3.21 ± 0.70. In total, 7 types of trinucleotide repeats were identified, each containing 7, 10, 11, 12, 13, 14, and 15 repeats, respectively. In the patients with (AAT)₇ allele, the distributions of the good and poor SPEM function groups were 18 (11.1%) and 19 (11.0%) respectively. In the patients with (AAT)₁₀ allele, (AAT)₁₁ allele, (AAT)₁₂ allele, (AAT)₁₃ allele, (AAT)₁₄ allele and (AAT)₁₅ allele, the distributions of good and poor SPEM function groups were 13 (8.0%) and 12 (7.0%), 4 (2.5%) and 6 (3.5%), 31 (19.8%) and 35 (20.3%), 51 (31.5%) and 51 (29.7%), 36 (22.2%) and 45 (26.2%), 9 (5.6%) and 4 (2.3%) respectively. As the number of (AAT) n repeat increased, there was no aggravation of abnormality of SPEM function. CONCLUSIONS: There was no significant aggravation of SPEM abnormality along with the increase of number of (AAT)n trinucleotide repeats in the CNR1 gene in Korean patients with schizophrenia.
Alleles
;
Endophenotypes
;
Eye Movements*
;
Gene Frequency
;
Humans
;
Logistic Models
;
Male
;
Pursuit, Smooth*
;
Receptors, Cannabinoid*
;
Schizophrenia*
;
Trinucleotide Repeats
7.Association Analysis between Chromogranin B Genetic Variations and Smooth Pursuit Eye Movement Abnormality in Korean Patients with Schizophrenia.
Jin Wan PARK ; Doo Hyun PAK ; Min Gyu HWANG ; Min Ji LEE ; Hyoung Doo SHIN ; Tae Min SHIN ; Sang Woo HAHN ; Jaeuk HWANG ; Yeon Jung LEE ; Sung Il WOO
Journal of the Korean Society of Biological Psychiatry 2018;25(4):101-109
OBJECTIVES: According to previous studies, the Chromogranin B (CHGB) gene could be an important candidate gene for schizophrenia which is located on chromosome 20p12.3. Some studies have linked the polymorphism in CHGB gene with the risk of schizophrenia. Meanwhile, smooth pursuit eye movement (SPEM) abnormality has been regarded as one of the most consistent endophenotype of schizophrenia. In this study, we investigated the association between the polymorphisms in CHGB gene and SPEM abnormality in Korean patients with schizophrenia. METHODS: We measured SPEM function in 24 Korean patients with schizophrenia (16 male, 8 female) and they were divided according to SPEM function into two groups, good and poor SPEM function groups. We also investigated genotypes of polymorphisms in CHGB gene in each group. A logistic regression analysis was performed to find the association between SPEM abnormality and the number of polymorphism. RESULTS: The natural logarithm value of signal/noise ratio (Ln S/N ratio) of good SPEM function group was 4.19 ± 0.19 and that of poor SPEM function group was 3.17 ± 0.65. In total, 15 single nucleotide polymorphisms of CHGB were identified and the genotypes were divided into C/C, C/R, and R/R. Statistical analysis revealed that two genetic variants (rs16991480, rs76791154) were associated with SPEM abnormality in schizophrenia (p = 0.004). CONCLUSIONS: Despite the limitations including a small number of samples and lack of functional study, our results suggest that genetic variants of CHGB may be associated with SPEM abnormality and provide useful preliminary information for further study.
Chromogranin B*
;
Endophenotypes
;
Eye Movements*
;
Genetic Variation*
;
Genotype
;
Humans
;
Logistic Models
;
Male
;
Polymorphism, Single Nucleotide
;
Pursuit, Smooth*
;
Schizophrenia*
8.Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years
Meerim PARK ; Jung Woo HAN ; Seung Min HAHN ; Jun Ah LEE ; Joo-Young KIM ; Sang Hoon SHIN ; Dong-Seok KIM ; Hong In YOON ; Kyung Taek HONG ; Jung Yoon CHOI ; Hyoung Jin KANG ; Hee Young SHIN ; Ji Hoon PHI ; Seung-Ki KIM ; Ji Won LEE ; Keon Hee YOO ; Ki Woong SUNG ; Hong Hoe KOO ; Do Hoon LIM ; Hyung Jin SHIN ; Hyery KIM ; Kyung-Nam KOH ; Ho Joon IM ; Seung Do AHN ; Young-Shin RA ; Hee-Jo BAEK ; Hoon KOOK ; Tae-Young JUNG ; Hyoung Soo CHOI ; Chae-Yong KIM ; Hyeon Jin PARK ; Chuhl Joo LYU
Cancer Research and Treatment 2021;53(2):378-388
Purpose:
Atypical teratoid/rhabdoid tumor (ATRT) is a highly aggressive malignancy with peak incidence in children aged less than 3 years. Standard treatment for central nervous system ATRT in children under the age of 3 years have not been established yet. The objective of this study was to analyze characteristics and clinical outcomes of ATRT in children aged less than 3 years.
Materials and Methods:
A search of medical records from seven centers was performed between January 2005 and December 2016.
Results:
Forty-three patients were enrolled. With a median follow-up of 90 months, 27 patients (64.3%) showed at least one episode of disease progression (PD). The first date of PD was at 160 days after diagnosis. The 1- and 3-year progression-free survivals (PFS) were 51.2% and 28.5%, respectively. The 1- and 3-year overall survivals were 61.9% and 38.1%, respectively. The 3-year PFS was improved from 0% in pre-2011 to 47.4% in post-2011. Excluding one patient who did not receive any further therapy after surgery, 27 patients died due to PD (n=21), treatment-related toxicity (n=5), or unknown cause (n=1). In univariate analysis, factors associated with higher 3-year PFS were no metastases, diagnosis after 2011, early adjuvant radiotherapy, and high-dose chemotherapy (HDCT). In multivariate analysis, the use of HDCT and adjuvant radiotherapy remained significant prognostic factors for PFS (both p < 0.01).
Conclusion
Aggressive therapy including early adjuvant radiotherapy and HDCT could be considered to improve outcomes of ATRT in children under the age of 3 years.
9.Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System in Children under the Age of 3 Years
Meerim PARK ; Jung Woo HAN ; Seung Min HAHN ; Jun Ah LEE ; Joo-Young KIM ; Sang Hoon SHIN ; Dong-Seok KIM ; Hong In YOON ; Kyung Taek HONG ; Jung Yoon CHOI ; Hyoung Jin KANG ; Hee Young SHIN ; Ji Hoon PHI ; Seung-Ki KIM ; Ji Won LEE ; Keon Hee YOO ; Ki Woong SUNG ; Hong Hoe KOO ; Do Hoon LIM ; Hyung Jin SHIN ; Hyery KIM ; Kyung-Nam KOH ; Ho Joon IM ; Seung Do AHN ; Young-Shin RA ; Hee-Jo BAEK ; Hoon KOOK ; Tae-Young JUNG ; Hyoung Soo CHOI ; Chae-Yong KIM ; Hyeon Jin PARK ; Chuhl Joo LYU
Cancer Research and Treatment 2021;53(2):378-388
Purpose:
Atypical teratoid/rhabdoid tumor (ATRT) is a highly aggressive malignancy with peak incidence in children aged less than 3 years. Standard treatment for central nervous system ATRT in children under the age of 3 years have not been established yet. The objective of this study was to analyze characteristics and clinical outcomes of ATRT in children aged less than 3 years.
Materials and Methods:
A search of medical records from seven centers was performed between January 2005 and December 2016.
Results:
Forty-three patients were enrolled. With a median follow-up of 90 months, 27 patients (64.3%) showed at least one episode of disease progression (PD). The first date of PD was at 160 days after diagnosis. The 1- and 3-year progression-free survivals (PFS) were 51.2% and 28.5%, respectively. The 1- and 3-year overall survivals were 61.9% and 38.1%, respectively. The 3-year PFS was improved from 0% in pre-2011 to 47.4% in post-2011. Excluding one patient who did not receive any further therapy after surgery, 27 patients died due to PD (n=21), treatment-related toxicity (n=5), or unknown cause (n=1). In univariate analysis, factors associated with higher 3-year PFS were no metastases, diagnosis after 2011, early adjuvant radiotherapy, and high-dose chemotherapy (HDCT). In multivariate analysis, the use of HDCT and adjuvant radiotherapy remained significant prognostic factors for PFS (both p < 0.01).
Conclusion
Aggressive therapy including early adjuvant radiotherapy and HDCT could be considered to improve outcomes of ATRT in children under the age of 3 years.
10.Effectiveness and Safety of Clofarabine Monotherapy or Combination Treatment in Relapsed/Refractory Childhood Acute Lymphoblastic Leukemia: A Pragmatic, Non-interventional Study in Korea
Jung Yoon CHOI ; Che Ry HONG ; Kyung Taek HONG ; Hyoung Jin KANG ; Seongkoo KIM ; Jae Wook LEE ; Pil Sang JANG ; Nack-Gyun CHUNG ; Bin CHO ; Hyery KIM ; Kyung-Nam KOH ; Ho Joon IM ; Jong Jin SEO ; Seung Min HAHN ; Jung Woo HAN ; Chuhl Joo LYU ; Eu Jeen YANG ; Young Tak LIM ; Keon Hee YOO ; Hong Hoe KOO ; Hoon KOOK ; In Sang JEON ; Hana CHO ; Hee Young SHIN
Cancer Research and Treatment 2021;53(4):1184-1194
Purpose:
Effectiveness and safety of clofarabine (one of the treatment mainstays in pediatric patients with relapsed/refractory acute lymphoblastic leukemia [ALL]) was assessed in Korean pediatric patients with ALL to facilitate conditional coverage with evidence development.
Materials and Methods:
In this multicenter, prospective, observational study, patients receiving clofarabine as mono/combination therapy were followed up every 4-6 weeks for 6 months or until hematopoietic stem cell transplantation (HSCT). Response rates, survival outcomes, and adverse events were assessed.
Results:
Sixty patients (2-26 years old; 65% B-cell ALL, received prior ≥ 2 regimen, 68.3% refractory to previous regimen) were enrolled and treated with at least one dose of clofarabine; of whom 26 (43.3%) completed 6 months of follow-up after the last dose of clofarabine. Fifty-eight patients (96.7%) received clofarabine combination therapy. Overall remission rate (complete remission [CR] or CR without platelet recovery [CRp]) was 45.0% (27/60; 95% confidence interval [CI], 32.4 to 57.6) and the overall response rate (CR, CRp, or partial remission [PR]) was 46.7% (28/60; 95% CI, 34.0 to 59.3), with 11 (18.3%), 16 (26.7%), and one (1.7%) patients achieving CR, CRp, and PR, respectively. The median time to remission was 5.1 weeks (95% CI, 4.7 to 6.1). Median duration of remission was 16.6 weeks (range, 2.0 to 167.6 weeks). Sixteen patients (26.7%) proceeded to HSCT. There were 24 deaths; 14 due to treatment-emergent adverse events.
Conclusion
Remission with clofarabine was observed in approximately half of the study patients who had overall expected safety profile; however, there was no favorable long-term survival outcome in this study.